Corcept Therapeutics Stock News

NEW YORK--(BUSINESS WIRE)-- #CORT--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Corcept Therapeutics Inc. (Corcept or the Company) (NASDAQ: CORT) on behalf of Corcept stockholders. Our investigation concerns whether Corcept has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On December 8, 2021, Corcept disclosed in a filing with the U

NEW YORK, Dec. 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Inc. ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The…

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / December 13, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Corcept Therapeutics Inc. ("Corcept" or the "Company") (NASDAQ:CORT). Investors who purchased Corcept sharesare encouraged to obtain additional information and assist the investigation by visiting the firm''s site: www.bgandg.com/cort. The investigation concerns whether Corcept and certain of its officers and/or directors have violated federal securities laws. On December 8, 2021, Corcept disclosed in a filing with the U.S. Securities and Exchange Commission that "[o]n November 15, 2021, the Company received a records subpoena from the U.S. Attorney''s Office for ..

TEVA PHARMACEUTICALS USA, INC., v. CORCEPT THERAPEUTICS, INC. Before Moore, Newman, and Reyna. Appeal from the Patent Trial and Appeal Board. Summary: Limitations, such as specific drug doses, in claim language can impact the application of the reasonable expectation of success analysis for obviousness. By: Knobbe Martens

Investors may be looking for a bargain after the company was hit with bad news this week.

Investors may be looking for a bargain after the company was hit with bad news this week.

Investors can contact the law firm at no cost to learn more about recovering their losses

Corcept Therapeutics Incorporated (NASDAQ:CORT) price on Thursday, December 09, fall -1.70% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $17.92. A look at the stock’s price movement, the level at last check in today’s session was $18.23, moving within a range at $15.825 and $19.05. The beta … A Stock Analysis Of Corcept Therapeutics Incorporated’s (CORT) Read More »

A U.S. attorney is interested in the company for the wrong reasons.

In the latest trading session, 4.19 million Corcept Therapeutics Incorporated (NASDAQ:CORT) shares changed hands as the companys beta touched 0.63. With the companys most recent per share price at $16.39 changed hands at -$5.55 or -25.30% at last look, the market valuation stands at $2.59B. CORTs current price is a discount, trading about -90.24% off Corcept Therapeutics Incorporated (NASDAQ: CORT): This Is The Year For Success Over The Next Few Months Read More »

A U.S. attorney is interested in the company for the wrong reasons.

MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (Corcept) a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that it has extended the expiration of its previously announced tender offer for shares of its common stock from one minute after 11:59 P.M., New York City time, on December 7, 2021 until one minute after 11:59 P.M., New York City time, on December 15, 2021 (unless further extended or earlier terminated).

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Brokerages expect Corcept Therapeutics Incorporated (NASDAQ:CORT) to report sales of $101.25 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Corcept Therapeutics earnings, with estimates ranging from $99.60 million to $102.90 million. Corcept Therapeutics posted sales of $85.74 million during the same quarter last year, which would indicate a []

SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Corcept Therapeutics, Inc. (NASDAQ: CORT) against certain of its officers and directors. Specifically, a class-action lawsuit pending in the Northern District of California issued an order denying in part the defendants'' motion to dismiss in the pending securities class action against Corcept.